Diligence memo · auto-generated · as of July 2, 2026
EarLens Corp
EarLens Corp looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
EarLens Corp operates in Other Health Care, based in MENLO PARK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EarLens Corp has raised $287M in disclosed capital across 13 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $72M on 2016-06-07.
Most recent recorded round closed around 2025-02-19.
Valuation (modeled)modeled
Provath models EarLens Corp at approximately $56M (range $29M–$77M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.25× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 2.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Other Health Care peers (5377 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: RESTOR3D, Inc., ByHeart, Inc., SpyGlassPharma, Inc., VantAI Holdings, Inc., BioIntelliSense, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.